tirzepatide
Regeneration vs degeneration — where this fits
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why it would work (logic chain)
No mechanism chain catalogued yet.
How many people take it
There is no reliable global count of how many people take this compound. That number is not in this ledger.
What we can count from this ledger:
- 0 anecdote source(s) (posts, threads, comments)
- 0 anecdote-tier claim(s) derived from them
Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.
Evidence inventory
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 8
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 8
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.2 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial (source s1)
2026 phase 3b SURMOUNT-MAINTAIN trial shows continuing tirzepatide MTD (10/15mg) maintains greater weight loss (-21.9%) vs placebo (-9.9%) after initial loss; dose reduction to 5mg also superior (-16.6%). Supports ongoing therapy for obesity management.
Evidence type: Published research.
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis (source s2)
2025 meta-analysis of trials confirms tirzepatide's dose-dependent weight loss (greater in non-diabetics), high odds of ≥5/10/15% loss, with mainly GI AEs but no increase in serious events.
Evidence type: Published research.
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database (source s3)
2025 observational study on real-world tirzepatide use and weight loss effectiveness in non-T2D patients.
Evidence type: Published research.
Tirzepatide for Obesity Treatment and Diabetes Prevention (source s4)
2025 NEJM phase 3 trial (SURMOUNT-1 extension) showing long-term weight loss and reduced T2D risk with tirzepatide.
Evidence type: Published research.
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 ... (source s5)
Phase 2 trial showing tirzepatide superior for weight loss in T1D adults with obesity.
Evidence type: Published research.
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial (source s6)
Subpopulation analysis from SURMOUNT-1 in Japanese participants showing weight loss benefits.
Evidence type: Published research.
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial (source s7)
RCT comparing tirzepatide to standard care in early T2D after 2 years.
Evidence type: Published research.
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study (source s8)
Real-world evidence on tirzepatide and reduced dementia risk in T2D.
Evidence type: Published research.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.